Prescription drug cost sharing: Associations with medication and medical utilization and spending and health

JAMA

Volumn 298, Issue 1, 2007, Pages 61-69

  Goldman, Dana P ^a,b   Joyce, Geoffrey F ^a   Zheng, Yuhui ^a  

^a RAND CORPORATION   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG COST; DRUG UTILIZATION; MEDLINE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; COST; ECONOMICS; FEE; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; STATISTICS; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

COST SHARING; DRUG COSTS; DRUG UTILIZATION; HEALTH SERVICES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRESCRIPTION FEES; UNITED STATES;

EID: 34347381507     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.1.61     Document Type: Review

References (144)

1. Lichtenberg FR. Are the benefits of newer drugs worth their cost? evidence from the 1996 MEPS. Health Aff (Millwood). 2001;20(5):241-251.
2. Gabel J, Levitt L, Holve E, et al. Job-based health benefits in 2002: some important trends. Health Aff (Millwood). 2002;21(5):143-151.
3. Prescription Drug Trends. Menlo Park, CA: Kaiser Family Foundation; June 2006:3057-4005.
4. Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients. JAMA. 2003;290(2):222-227.
5. Andersson K, Petzold MG, Sonesson C, Lonnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy. 2006;79(2-3):231-243.
6. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157-1164.
7. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006;28(6):964-978.
8. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. December 2006;12 (special issue):SP11-SP19.
9. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006; 12(9):509-517.
10. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006; 12(1):21-28.
11. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319-1331.
12. Li X, Guh D, Lacaille D, Esdaile J, Anis AH. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: ownand cross-price elasticities [published online ahead of print November 27, 2006]. Health Policy. doi:10.1016/j.healthpol.2006.11.002.
13. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-683.
14. Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med Care Res Rev. 2006;63(6):742-763.
15. Anis AH, Guh DP, Lacaille D, et al. When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions. CMAJ. 2005;173(11): 1335-1340.
16. Contoyannis P, Hurley J, Grootendorst P, Jeon SH, Tamblyn R. Estimating the price elasticity of expenditure for prescription drugs in the presence of nonlinear price schedules: an illustration from Quebec, Canada. Health Econ. 2005;14(9):909-923.
17. Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry. 2005;42(3):293-310.
18. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clin Ther. 2005;27(9):1478-1487.
19. Huskamp HA, Deverka PA, Epstein AM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry. 2005;62(4):435-441.
20. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost sharing on drug utilization. Am J Manag Care. 2005;11(10):621-628.
21. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5)(suppl):S170-S176.
22. Roblin DW, Platt R, Goodman MJ, et al. Effect of increased cost sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care. 2005;43(10):951-959.
23. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2004;164(15):1679-1684.
24. Crown WH, Berndt ER, Baser O, et al. Benefit plan design and prescription drug utilization among asthmatics: do patient copayments matter? Front Health Policy Res. 2004;7:95-127.
25. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
26. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
27. Kamal-Bahl S, Briesacher B. How do incentive-based formularies influence drug selection and spending for hypertension? Health Aff (Millwood). 2004;23(1):227-236.
28. Liu SZ, Romeis JC. Changes in drug utilization following the outpatient prescription drug cost sharing program - evidence from Taiwan's elderly. Health Policy. 2004;68(3):277-287.
29. Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am J Health Syst Pharm. 2004;61(3):267-272.
30. Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids. J Manag Care Pharm. 2004; 10(3):226-233.
31. Winkelmann R. Co-payments for prescription drugs and the demand for doctor visits - evidence from a natural experiment. Health Econ. 2004;13(11):1081-1089.
32. Blais L, Couture J, Rahme E, LeLorier J. Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance. Health Policy. 2003;64(2):163-172.
33. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12):3147-3161.
34. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.
35. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. Med Care. 2003;41(12):1331-1342.
36. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9(2):123-133.
37. Ong M, Catalano R, Hartig T. A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clin Ther. 2003;25(4):1262-1275.
38. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41(3):398-406.
39. Artz MB, Hadsall RS, Schondelmeyer SW. Impact of generosity level of outpatient prescription drug coverage on prescription drug events and expenditure among older persons. Am J Public Health. 2002; 92(8):1257-1263.
40. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
41. Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002; 167(3):246-252.
42. Thomas CP, Wallack SS, Lee S, Ritter GA. Impact of health plan design and management on retirees' prescription drug use and spending, 2001. Health Aff (Millwood). July-December 2002(suppl Web exclusives): W408-W419.
43. Balkrishnan R, Byerly WG, Camacho FT, Shrestha A, Anderson RT. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population. Am J Manag Care. 2001;7(11):1093-1100.
44. Blais L, Boucher JM, Couture J, Rahme E, Le-Lorier J. Impact of a cost sharing drug insurance plan on drug utilization among older people. J Am Geriatr Soc. 2001;49(4):410-414.
45. Kozyrskyj AL, Mustard CA, Cheang MS, Simons FE. Income-based drug benefit policy: impact on receipt of inhaled corticosteroid prescriptions by Manitoba children with asthma. CMAJ. 2001;165(7):897-902.
46. Kozyrskyj AL, Mustard CA, Simons FE. Socioeconomic status, drug insurance benefits, and new prescriptions for inhaled corticosteroids in schoolchildren with asthma. Arch Pediatr Adolesc Med. 2001; 155(11):1219-1224.
47. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-1304.
48. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost sharing among poor and elderly persons. JAMA. 2001;285 (4):421-429.
49. Hillman AL, Pauly MV, Escarce JJ, et al. Financial incentives and drug spending in managed care. Health Aff (Millwood). 1999;18(2):189-200.
50. Motheral BR, Henderson R. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Manag Care. 1999;5(11):1383-1394.
51. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-212.
52. Berndt ER, Frank RG, McGuire TG. Alternative insurance arrangements and the treatment of depression: what are the facts? Am J Manag Care. 1997;3 (2):243-250.
53. Grootendorst PV, O'Brien BJ, Anderson GM. On becoming 65 in Ontario: effects of drug plan eligibility on use of prescription medicines. Med Care. 1997; 35(4):386-398.
54. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35(11):1119-1131.
55. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Serv Res. 1997;32(1):103-122.
56. Hong SH, Shepherd MD. Outpatient prescription drug use by children enrolled in five drug benefit plans. Clin Ther. 1996;18(3):528-545.
57. McManus P, Donnelly N, Henry D, Hall W, Primrose J, Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf. 1996;5(6):385-392.
58. Coulson NE, Stuart BC. Insurance choice and the demand for prescription drugs. South Econ J. 1995;61(4):1146-1157.
59. Hughes D, McGuire A. Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure. Health Econ. 1995;4(3):213-220.
60. Smith DG. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry. 1993;30(2):189-198.
61. Ryan M, Birch S. Charging for health care: evidence on the utilisation of NHS prescribed drugs. Soc Sci Med. 1991;33(6):681-687.
62. Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28(10):907-917.
63. Lingle E, Reeder C, Kozma C. Impact of an open formulary system on the utilization of medical services. J Res Pharm Econ. 1990;2:93-123.
64. Lavers RJ. Prescription charges, the demand for prescriptions and morbidity. Appl Econ. 1989;21(8):1043-1052.
65. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ. 1989;8(1):109-132.
66. Foxman B, Valdez RB, Lohr KN, Goldberg GA, Newhouse JP, Brook RH. The effect of cost sharing on the use of antibiotics in ambulatory care: results from a population-based randomized controlled trial. J Chronic Dis. 1987;40(5):429-437.
67. Birch S. Relationship between increasing prescription charges and consumption in groups not exempt from charges. J R Coll Gen Pract. 1986;36(285):154-156.
68. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc Sci Med. 1985;21(10):1063-1069.
69. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry. 1985;22(4):396-403.
70. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359.
71. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-960.
72. Cox ER, Henderson RR. Prescription use behavior among medicare beneficiaries with capped prescription benefits. J Manag Care Pharm. 2002;8(5):360-364.
73. Cox ER, Jernigan C, Coons SJ, Draugalis JL. Medicare beneficiaries' management of capped prescription benefits. Med Care. 2001;39(3):296-301.
74. Fortess EE, Soumerai SB, McLaughlin TJ, Ross-Degnan D. Utilization of essential medications by vulnerable older people after a drug benefit cap: importance of mental disorders, chronic pain, and practice setting. J Am Geriatr Soc. 2001;49(6):793-797.
75. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients: effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996;34(7):686-701.
76. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655.
77. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072-1077.
78. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550-556.
79. Abdelgawad T, Egbuonu-Davis L. Preferred drug lists and Medicaid prescriptions. Pharmacoeconomics. 2006;24(suppl 3):55-63.
80. Ackman ML, Graham MM, Hui C, Tsuyuki RT. Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting. Can J Cardiol. 2006; 22(14):1205-1208.
81. Carroll NV, Smith JC, Berringer RA, Oestreich GL. Evaluation of an automated system for prior authorization: a COX-2 inhibitor example. Am J Manag Care. 2006;12(9):501-508.
82. Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12 (4):294-302.
83. Kahan NR, Chinitz DP, Waitman DA, Kahan E. When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians. Br J Clin Pharmacol. 2006;61(3):341-344.
84. Ridley DB, Axelsen KJ. Impact of medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24(suppl 3):65-78.
85. Roughead EE, Zhang F, Ross-Degnan D, Soumerai S. Differential effect of early or late implementation of prior authorization policies on the use of COX II inhibitors. Med Care. 2006;44(4):378-382.
86. Spence MM, Hui R, Chan J. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit. J Manag Care Pharm. 2006;12 (5):377-382.
87. Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM. Effect of generic-only drug benefits on seniors' medication use and financial burden. Am J Manag Care. 2006;12(9):525-532.
88. West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2006;12(1):25-32.
89. Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff (Millwood). 2005;24(3):780-789.
90. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
91. Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy. 2005;25(7):924-934.
92. Lichtenberg FR. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. Am J Manag Care. January 2005;11(special issue): SP7-SP13.
93. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care. January 2005;11(special issue):SP35-SP42.
94. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. January 2005;11(special issue):SP14-SP20.
95. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. January 2005;11(special issue):SP27-SP34.
96. Christian-Herman J, Emons M, George D. Effects of generic-only drug coverage in a Medicare HMO. Health Aff (Millwood). July-December 2004 (suppl Web exclusives):W4-455-W4-468.
97. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-2194.
98. Harris BN, West DS, Johnson J, Hong SH, Stowe CD. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2004;10(5):449-455.
99. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther. 2004;26(9):1518-1532.
100. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care. 2004;10(7 pt 1):457-464.
101. Campbell CA, Cooke CA, Weerasinghe SD, Sketris IS, McLean-Veysey PR, Skedgel CD. Topical corticosteroid prescribing patterns following changes in drug benefit status. Ann Pharmacother. 2003;37(6):787-793.
102. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003;22(3):149-158.
103. Wang YR, Pauly MV, Lin YA. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary. Am J Manag Care. 2003;9(10):686-696.
104. McCombs JS, Shi L, Stimmel GL, Croghan TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24(11):1939-1959.
105. Cromwell DM, Bass EB, Steinberg EP, et al. Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations? Health Serv Res. 1999;33(6):1593-1610.
106. Motheral BR, Henderson R. The effect of a closed formulary on prescription drug use and costs. Inquiry. 1999;36(4):481-491.
107. Streja DA, Hui RL, Streja E, McCombs JS. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Manag Care. 1999; 5(9):1133-1142.
108. Horn SD, Sharkey PD, Phillips-Harris C. Formulary limitations and the elderly: results from the Managed Care Outcomes Project. Am J Manag Care. 1998;4(8):1105-1113.
109. Phillips CR, Larson LN. Evaluating the operational performance and financial effects of a drug prior authorization program. J Manag Care Pharm. 1997;(3):699-706.
110. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25(2):230-239.
111. Jones DL, Kroenke K, Landry FJ, Tomich DJ, Ferrel RJ. Cost savings using a stepped-care prescribing protocol for nonsteroidal anti-inflammatory drugs. JAMA. 1996;275(12):926-930.
112. Kotzan J, Perri M, Martin B. Assessment of Medicaid prior-approval policies on prescription expenditures: market-share analysis of Medicaid and cash prescriptions. J Manag Care Pharm. 1996;2(6): 651-656.
113. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332(24):1612-1617.
114. Kotzan JA, McMillan JA, Jankel CA, Foster AL. Initial impact of a Medicaid prior authorization program for NSAID prescriptions. J Res Pharm Econ. 1993; 5(1):25-41.
115. Kotzan JA, Jankel CA, McMillan JA, Foster AL, Myers S. Initial impact of a Medicaid maintenance dose program for H2 antagonist prescriptions. J Res Pharm Econ. 1993;5(1):43-58.
116. Moore WJ, Newman RJ. Drug formulary restrictions as a cost-containment policy in Medicaid programs. J Law Econ. 1993;36(1):71-97.
117. Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care. 1990;28(10):963-977.
118. Kreling DH, Knocke DJ, Hammel RW. The effects of an internal analgesic formulary restriction on Medicaid drug expenditures in Wisconsin. Med Care. 1989;27(1):34-44.
119. Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care. 1985;23(7):872-880.
120. Mabasa VH, Ma J. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada. J Manag Care Pharm. 2006;12(5):371-376.
121. Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006;79(4):379-388.
122. Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv Res. 2005;40(5 pt 1):1297-1317.
123. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care. 2004;42(7):653-660.
124. Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004;328(7439):560.
125. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003;74(4):388-400.
126. Hazlet TK, Blough DK. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly. Med Care. 2002;40(8):640-649.
127. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. CMAJ. 2002;166(13):1655-1662.
128. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002;166(6):737-745.
129. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346(11):822-829.
130. Aronsson T, Bergman MA, Rudholm N. The impact of generic drug competition on brand name market shares - evidence from micro data. Rev Ind Organ. 2001;19(4):425-435.
131. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. CMAJ. 2001;165(8):1011-1019.
132. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiol Drug Saf. 2001;10(4):295-300.
133. Narine L, Senathirajah M, Smith T. An assessment of the impact of reference-based pricing policies on the H2 antagonist market in British Columbia, Canada. J Res Pharmaceutical Econ. 2001;11 (1):63-78.
134. Narine L, Senathirajah M, Smith T. Evaluating reference-based pricing: initial findings and prospects. CMAJ. 1999;161(3):286-288.
135. Jönsson B. Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics. 1994;6(suppl 1):51-60.
136. Rector TS. Exhaustion of drug benefits and dis-enrollment of medicare beneficiaries from managed care organizations. JAMA. 2000;283(16):2163- 2167.
137. Lingle EW Jr, Kirk KW, Kelly WR. The impact of outpatient drug benefits on the use and costs of health care services for the elderly. Inquiry. 1987;24(3):203-211.
138. Smith DG, Kirking DM. Impact of consumer fees on drug utilisation. Pharmacoeconomics. 1992;2(4):335-342.
139. Cunningham PJ. Prescription drug access: not just a Medicare problem. Issue Brief Cent Stud Health Syst Change. April 2002;(51):1-4.
140. Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care. 1998;36(2):202-211.
141. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868-2879.
142. Topol EJ. Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med. 2004;350(15):1562-1564.
143. Reed MC. An Update on Americans' Access to Prescription Drugs. Washington, DC: Center for Styding Health System Change; May 2005. Issue Brief 95. http://www.hschange.com/CONTENT/738/.
144. Goldman DP, Smith JP. Methodological biases in estimating the burden of out-of-pocket expenses. Health Serv Res. 2001;35(6):1357-1365.